rcAAV Testing

While AAV vectors are engineered to be replication defective, generation of replication-competent AAV (rcAAV) can still occur during vector manufacturing by means of recombination events within the producer cells. rcAAV may develop at any step during the manufacturing process of gene therapy products. Even though vector production systems have been specifically developed to reduce the risk of rcAAV generation, there is still a significant safety concern driving the recommendations for testing for rcAAV in cell banks, vector and final product release for AAV-based gene therapy products.

		From	To	From	To	From	To
Monday	Open	9:00am	5:00pm
Tuesday	Open	9:00am	5:00pm
Wednesday	Open	9:00am	5:00pm
Thursday	Open	9:00am	5:00pm
Friday	Open	9:00am	5:00pm
Saturday	Open	9:00am	5:00pm
Sunday	Open